Cambridge Catalogue  
  • Help
Home > Catalogue > Outcomes Assessment in Cancer
Outcomes Assessment in Cancer
Google Book Search

Search this book


  • Page extent: 676 pages
  • Size: 247 x 174 mm
  • Weight: 1.663 kg


 (ISBN-13: 9780521838900 | ISBN-10: 0521838908)


  List of contributors page ix
  Acknowledgments xiii
1   Introduction to Outcomes Assessment in Cancer 1
  Joseph Lipscomb, Ph.D., Carolyn C. Gotay, Ph.D., and Claire Snyder, M.H.S. (The Editors)
Health-related quality of life in cancer: general concepts and generic measures
2   Definitions and conceptual models of quality of life 14
  Carol Estwing Ferrans, Ph.D., R.N., F.A.A.N.
3   Assessing health status and quality of life of cancer patients: the use of general instruments 31
  Pennifer Erickson, Ph.D.
4   The roles for preference-based measures in support of cancer research and policy 69
  David H. Feeny, Ph.D.
Assessing health-related quality of life during treatment
5   Quality of life in breast cancer: what have we learned and where do we go from here? 93
  Patricia A. Ganz, M.D., and Pamela J. Goodwin, M.D., M.Sc.
6   Measuring quality of life in prostate cancer: progress and challenges 126
  Mark S. Litwin, M.D., M.P.H., and James A. Talcott, M.D., S.M.
7   The science of quality-of-life measurement in lung cancer 160
  Craig C. Earle, M.D., M.Sc., and Jane C. Weeks, M.D.
8   Treatment for colorectal cancer: impact on health-related quality of life 178
  Carol M. Moinpour, Ph.D., and Dawn Provenzale, M.D., M.S.
9   Instruments to measure the specific health impact of surgery, radiation, and chemotherapy on cancer patients 201
  Michael J. Barry, M.D., and Janet E. Dancey, M.D.
Assessing health-related quality of life across the cancer continuum
10   Short-term outcomes of chemoprevention, genetic susceptibility testing, and screening interventions: What are they? How are they measured? When should they be measured? 216
  Jeanne S. Mandelblatt, M.D., M.P.H., and Joe V. Selby, M.D., M.P.H.
11   Evaluating quality of life in cancer survivors 241
  Brad Zebrack, Ph.D., M.S.W., and David Cella, Ph.D.
12   Assessing health-related quality of life at end of life 264
  Betty R. Ferrell, Ph.D., F.A.A.N.
Measuring the experience and needs of cancer patients and caregivers
13   Patient advocate perspective on health-related quality of life issues with prostate cancer survivors 286
  (Col. Ret.) James E. Williams, Jr.
14   Measuring the patient’s perspective on the interpersonal aspects of cancer care 290
  Charles Darby
15   Needs assessment in cancer 305
  David H. Gustafson, Ph.D.
16   Assessing the subjective impact of caregiving on informal caregivers of cancer patients 329
  Claire Snyder, M.H.S.
Methodological considerations in applications to cancer outcomes research
17   Practical considerations in outcomes assessment for clinical trials 346
  Diane L. Fairclough, Dr.P.H.
18   Statistical issues in the application of cancer outcome measures 362
  Jeff A. Sloan, Ph.D.
19   The clinical value and meaning of health-related quality-of-life outcomes in oncology 386
  David Osoba, B.Sc., M.D., F.R.C.P.C.
20   Cross-cultural use of health-related quality of life assessments in clinical oncology 406
  Neil K. Aaronson, Ph.D.
Modern psychometric theory in cancer outcomes research
21   Item response theory and its applications for cancer outcomes measurement 425
  Steven P. Reise, Ph.D.
22   Applications of item response theory to improve health outcomes assessment: developing item banks, linking instruments, and computer-adaptive testing 445
  Ronald K. Hambleton, Ph.D.
23   Subscales and summary scales: issues in health-related outcomes 465
  Mark Wilson, Ph.D.
Assessing the economic impact of cancer
24   On the definition and measurement of the economic burden of cancer 480
  Mark C. Hornbrook, Ph.D.
25   Cost-effectiveness analysis in cancer: toward an iterative framework for integration of evidence from trials and models 503
  Bernie J. O’Brien, Ph.D.
Research and policy implications
26   Data for cancer outcomes research: identifying and strengthening the empirical base 522
  Carolyn C. Gotay, Ph.D., and Joseph Lipscomb, Ph.D.
27   Use of health-related quality of life measures by industry and regulatory agencies in evaluating oncology therapies 550
  Dennis A. Revicki, Ph.D.
28   Reflections on COMWG findings and moving to the next phase 568
  Carolyn C. Gotay, Ph.D., Joseph Lipscomb, Ph.D., and Claire Snyder, M.H.S.
Invited papers
  Invited Paper A The world of outcomes research: yesterday, today, and tomorrow 584
  Bert Spilker, Ph.D., M.D.
  Invited Paper B The ten Ds of health outcomes measurement for the twenty-first century 590
  Colleen A. McHorney, Ph.D., and Karon F. Cook, Ph.D.
  Invited Paper C The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment 610
  Gordon B. Willis, Ph.D., Bryce B. Reeve, Ph.D., and Ivan Barofsky, Ph.D.
  Invited Paper D Industry perspective regarding outcomes research in oncology 623
  Kati Copley-Merriman, M.S., M.B.A., Joseph Jackson, Ph.D., J. Gregory Boyer, Ph.D., Joseph C. Cappelleri, Ph.D., M.P.H., Robert DeMarinis, Ph.D., Joseph DiCesare, M.P.H., R.Ph., M. Haim Erder, Ph.D., Jean Paul Gagnon, Ph.D., Lou Garrison, Ph.D., Kathleen Gondek, Ph.D., Kim A. Heithoff, Sc.D., Tom Hughes, Ph.D., David Miller, Ph.D., Margaret Rothman, Ph.D., Nancy Santanello, M.D., M.S., Richard Willke, Ph.D., and Bruce Wong, M.D.
  Index 639

printer iconPrinter friendly version AddThis